Edesa Biotech (EDSA) CEO-linked entity acquires 10,000 common shares

Rhea-AI Filing Summary

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of Common Shares. On March 4, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by him, bought 10,000 Common Shares at a price of $4.2560 per share. Following this transaction, that entity was reported to hold 392,702 Common Shares indirectly.

As of the same date, Nijhawan also reported 627,813 Common Shares held directly. Indirect holdings were additionally reported as 32,609 Common Shares held by The New Nijhawan Family Trust 2015, 32,013 Common Shares held by The Digestive Health Clinic Inc., and 53,104 Common Shares held by 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/04/2026		P		10,000	A	$4.256	392,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(1)
Common Shares								627,813	D
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(1)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160 Ontario Inc.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edesa Biotech (EDSA) disclose for Pardeep Nijhawan?

Edesa Biotech disclosed that Pardeep Nijhawan reported an indirect open-market purchase of 10,000 Common Shares at $4.2560 per share on March 4, 2026. The shares were bought through Pardeep Nijhawan Medicine Professional Corporation, which is wholly owned by him.

How many Edesa Biotech (EDSA) shares were purchased and at what price?

An entity wholly owned by Pardeep Nijhawan purchased 10,000 Edesa Biotech Common Shares at $4.2560 per share on March 4, 2026. This open-market transaction increased that entity’s reported indirect holdings to 392,702 Common Shares as of the same date.

Is the Edesa Biotech (EDSA) share purchase by Pardeep Nijhawan direct or indirect?

The reported purchase is indirect. The 10,000 Common Shares were bought by Pardeep Nijhawan Medicine Professional Corporation, which is wholly owned by him. The filing classifies this as indirect ownership and includes a disclaimer of beneficial ownership except for his pecuniary interest.

What are Pardeep Nijhawan’s reported direct Edesa Biotech (EDSA) holdings?

As of March 4, 2026, Pardeep Nijhawan reported direct ownership of 627,813 Edesa Biotech Common Shares. This figure appears as the total shares following the reported transactions and is separate from his indirect holdings through various entities and a family trust.

What indirect Edesa Biotech (EDSA) holdings are reported through entities and trusts?

As of March 4, 2026, reported indirect holdings include 392,702 Common Shares via Pardeep Nijhawan Medicine Professional Corporation, 32,609 via The New Nijhawan Family Trust 2015, 32,013 via The Digestive Health Clinic Inc., and 53,104 via 1968160 Ontario Inc., with beneficial ownership disclaimed except for pecuniary interest.

What does the Form 4 say about Pardeep Nijhawan’s beneficial ownership in Edesa Biotech (EDSA)?

The Form 4 states that several holding entities are wholly owned by, or co-trusteeed with, Pardeep Nijhawan. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, and their inclusion is not an admission of full beneficial ownership.